Go/no-go decision for early asset
The challenge
With several other in-class competitors, a client sought Putnam’s guidance on a go/no-go development decision for a first-generation targeted therapy in Phase 1 clinical development.
Our solution
We worked to understand its projected value proposition and commercial viability by assessing the competitive landscape and development approaches, prioritizing opportunities, developing target profiles and value propositions, validating with KOLs, and using base- and best-case assumptions.
The results
We provided the revenue potential of the asset by scenario for visibility on what revenue gaps the asset could fill over a period of time, leading to the client’s go/no-go decision for the early asset.
Jump to a slide with the slide dots.
Patient Finding Through Data Tokenization
Refined HCP targeting in rare disease using integrated data, boosting hit rates from 10% to 50% and delivering 3x ROI in 6 months.
Read moreDigital share of voice and sentiment analysis at key congress
Used GenAI to benchmark digital voice in oncology, boosting engagement & leadership via LinkedIn, DEI & clinical messaging.
Read moreData Strategy Development
Future-proofed data strategy with Putnam: gaps identified, vendors vetted, leading to a first US multi-source tokenized DB.
Read more